This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by File, T. M.
Right arrow Articles by Rubin, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by File, T. M., Jr
Right arrow Articles by Rubin, A.

 Previous Article  |  Next Article 




This article has been cited by other articles:

  • Lim, W S, Baudouin, S V, George, R C, Hill, A T, Jamieson, C, Le Jeune, I, Macfarlane, J T, Read, R C, Roberts, H J, Levy, M L, Wani, M, Woodhead, M A, Pneumonia Guidelines Committee of the BTS Standard, (2009). BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64: iii1-iii55 [Full Text]  
  • Bulitta, J. B., Landersdorfer, C. B., Kinzig, M., Holzgrabe, U., Sorgel, F. (2009). New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics. Antimicrob. Agents Chemother. 53: 3462-3471 [Abstract] [Full Text]  
  • Vardakas, K. Z. MD, Siempos, I. I. MD, Grammatikos, A. MD, Athanassa, Z. MD, Korbila, I. P. MD, Falagas, M. E. MD DSc (2008). Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 179: 1269-1277 [Abstract] [Full Text]  
  • Aspa, J., Rajas, O., Rodriguez de Castro, F., Huertas, M. C., Borderias, L., Cabello, F. J., Tabara, J., Hernandez-Flix, S., Martinez-Sanchis, A., Torres, A. (2006). Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 27: 1010-1019 [Abstract] [Full Text]  
  • Kennedy, C. C., Aksamit, T. R. (2006). 33-Year-Old Woman With Pleuritic Chest Pain and Nonproductive Cough. Mayo Clin Proc. 81: 85-88 [Full Text]  
  • Woodhead, M., Blasi, F., Ewig, S., Huchon, G., Leven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., Verheij, T. J. M. (2005). Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26: 1138-1180 [Abstract] [Full Text]  
  • Shefet, D., Robenshtok, E., Paul, M., Leibovici, L. (2005). Empirical Atypical Coverage for Inpatients With Community-Acquired Pneumonia: Systematic Review of Randomized Controlled Trials. Arch Intern Med 165: 1992-2000 [Abstract] [Full Text]  
  • van der Eerden, M M, Vlaspolder, F, de Graaff, C S, Groot, T, Bronsveld, W, Jansen, H M, Boersma, W G (2005). Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 60: 672-678 [Abstract] [Full Text]  
  • Mizunaga, S., Kamiyama, T., Fukuda, Y., Takahata, M., Mitsuyama, J. (2005). Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems. J Antimicrob Chemother 56: 91-96 [Abstract] [Full Text]  
  • Leroy, O., Saux, P., Bedos, J.-P., Caulin, E., for the Levofloxacin Study Group, (2005). Comparison of Levofloxacin and Cefotaxime Combined With Ofloxacin for ICU Patients With Community-Acquired Pneumonia Who Do Not Require Vasopressors. Chest 128: 172-183 [Abstract] [Full Text]  
  • Waites, K. B., Talkington, D. F. (2004). Mycoplasma pneumoniae and Its Role as a Human Pathogen. Clin. Microbiol. Rev. 17: 697-728 [Abstract] [Full Text]  
  • Blasi, F. (2004). Atypical pathogens and respiratory tract infections. Eur Respir J 24: 171-182 [Abstract] [Full Text]  
  • Brown, R. B. (2004). Legionella Pneumonia: The Spectrum Continues to Expand. Chest 125: 1979-1980 [Full Text]  
  • Yu, V. L., Greenberg, R. N., Zadeikis, N., Stout, J. E., Khashab, M. M., Olson, W. H., Tennenberg, A. M. (2004). Levofloxacin Efficacy in the Treatment of Community-Acquired Legionellosis. Chest 125: 2135-2139 [Abstract] [Full Text]  
  • Bostock, J. M., Geary, I., Eley, A., Chopra, I. (2004). Mecillinam has potent in vitro activity against Chlamydophila pneumoniae ATCC VR1310. J Antimicrob Chemother 53: 1112-1112 [Full Text]  
  • Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
  • File, T. M. Jr, Garau, J., Blasi, F., Chidiac, C., Klugman, K., Lode, H., Lonks, J. R., Mandell, L., Ramirez, J., Yu, V. (2004). Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia. Chest 125: 1888-1901 [Abstract] [Full Text]  
  • Powers, J. H., Cooper, C. K. (2004). Evaluating Combination Therapy in Community-Acquired Pneumonia. Chest 125: 353-353 [Full Text]  
  • Oosterheert, J. J., Bonten, M. J. M., Hak, E., Schneider, M. M. E., Hoepelman, I. M. (2003). How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. J Antimicrob Chemother 52: 555-563 [Abstract] [Full Text]  
  • Rodvold, K. A., Danziger, L. H., Gotfried, M. H. (2003). Steady-State Plasma and Bronchopulmonary Concentrations of Intravenous Levofloxacin and Azithromycin in Healthy Adults. Antimicrob. Agents Chemother. 47: 2450-2457 [Abstract] [Full Text]  
  • Torres, A., Muir, J-F., Corris, P., Kubin, R., Duprat-Lomon, I., Sagnier, P-P., Hoffken, G. (2003). Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 21: 135-143 [Abstract] [Full Text]  
  • Furlanut, M., Brollo, L., Lugatti, E., Di Qual, E., Dolcet, F., Talmassons, G., Pea, F. (2003). Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother 51: 101-106 [Abstract] [Full Text]  
  • Croisier, D., Chavanet, P., Lequeu, C., Ahanou, A., Nierlich, A., Neuwirth, C., Piroth, L., Duong, M., Buisson, M., Portier, H. (2002). Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50: 349-360 [Abstract] [Full Text]  
  • Ortqvist, A. (2002). Treatment of community-acquired lower respiratory tract infections in adults. Eur Respir J 20: 40S-53s [Abstract] [Full Text]  
  • Finch, R., Schurmann, D., Collins, O., Kubin, R., McGivern, J., Bobbaers, H., Izquierdo, J. L., Nikolaides, P., Ogundare, F., Raz, R., Zuck, P., Hoeffken, G. (2002). Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment. Antimicrob. Agents Chemother. 46: 1746-1754 [Abstract] [Full Text]  
  • Low, D. E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D., Forward, K., Zhanel, G., Simor, A., McGeer, A. (2002). Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. 46: 1295-1301 [Abstract] [Full Text]  
  • Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C.S., Kibsey, P., Fleming, C., Low, D. E. (2002). Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia. NEJM 346: 747-750 [Full Text]  
  • Boman, J., Hammerschlag, M. R. (2002). Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies. Clin. Microbiol. Rev. 15: 1-20 [Abstract] [Full Text]  
  • Ball, P., Baquero, F., Cars, O., File, T., Garau, J., Klugman, K., Low, D. E., Rubinstein, E., Wise, R., Consensus Group on Resistance and Prescribing in R, T. (2002). Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 49: 31-40 [Abstract] [Full Text]  
  • Baden, L. R., Horowitz, G., Jacoby, H., Eliopoulos, G. M. (2001). Quinolones and False-Positive Urine Screening for Opiates by Immunoassay Technology. JAMA 286: 3115-3119 [Abstract] [Full Text]  
  • Guthrie, R. (2001). Community-Acquired Lower Respiratory Tract Infections : Etiology and Treatment. Chest 120: 2021-2034 [Abstract] [Full Text]  
  • (2001). BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 56: iv1-64 [Full Text]  
  • Gupta, S. K., Imperiale, T. F., Sarosi, G. A. (2001). Evaluation of the Winthrop-University Hospital Criteria to Identify Legionella Pneumonia. Chest 120: 1064-1071 [Abstract] [Full Text]  
  • Waterer, G. W., Somes, G. W., Wunderink, R. G. (2001). Monotherapy May Be Suboptimal for Severe Bacteremic Pneumococcal Pneumonia. Arch Intern Med 161: 1837-1842 [Abstract] [Full Text]  
  • Frothingham, R., Dowell, S. F., Heffelfinger, J. D. (2001). Quinolones for Community-Acquired Pneumonia. Arch Intern Med 161: 1681-1682 [Full Text]  
  • Chow, A. T., Fowler, C., Williams, R. R., Morgan, N., Kaminski, S., Natarajan, J. (2001). Safety and Pharmacokinetics of Multiple 750-Milligram Doses of Intravenous Levofloxacin in Healthy Volunteers. Antimicrob. Agents Chemother. 45: 2122-2125 [Abstract] [Full Text]  
  • Jones, R. N. (2001). Conventional dogma applied to quinolones? Time for a change. J Antimicrob Chemother 47: 893-893 [Full Text]  
  • Niederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D., Dean, N., File, T., Fine, M. J., Gross, P. A., Martinez, F., Marrie, T. J., Plouffe, J. F., Ramirez, J., Sarosi, G. A., Torres, A., Wilson, R., Yu, V. L. (2001). Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention. Am. J. Respir. Crit. Care Med. 163: 1730-1754 [Full Text]  
  • Dresser, L. D., Niederman, M. S., Paladino, J. A. (2001). Cost-effectiveness of Gatifloxacin vs Ceftriaxone With a Macrolide for the Treatment of Community-Acquired Pneumonia. Chest 119: 1439-1448 [Abstract] [Full Text]  
  • Cohen, M., Sahn, S. A. (2001). Resolution of Pleural Effusions. Chest 119: 1547-1562 [Full Text]  
  • Zhanel, G. G., Walters, M., Laing, N., Hoban, D. J. (2001). In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J Antimicrob Chemother 47: 435-440 [Abstract] [Full Text]  
  • Gotfried, M. H., Danziger, L. H., Rodvold, K. A. (2001). Steady-State Plasma and Intrapulmonary Concentrations of Levofloxacin and Ciprofloxacin in Healthy Adult Subjects. Chest 119: 1114-1122 [Abstract] [Full Text]  
  • Macfarlane, J, Holmes, W, Gard, P, Macfarlane, R, Rose, D, Weston, V, Leinonen, M, Saikku, P, Myint, S (2001). Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 56: 109-114 [Abstract] [Full Text]  
  • Cubbon, M. D., Masterton, R. G. (2000). New quinolones--a fresh answer to the pneumococcus. J Antimicrob Chemother 46: 869-872 [Full Text]  
  • Plouffe, J., Schwartz, D. B., Kolokathis, A., Sherman, B. W., Arnow, P. M., Gezon, J. A., Suh, B., Anzuetto, A., Greenberg, R. N., Niederman, M., Paladino, J. A., Ramirez, J. A., Inverso, J., Knirsch, C. A., the Azithromycin Intravenous Clinical Trials Group, (2000). Clinical Efficacy of Intravenous followed by Oral Azithromycin Monotherapy in Hospitalized Patients with Community-Acquired Pneumonia. Antimicrob. Agents Chemother. 44: 1796-1802 [Abstract] [Full Text]  
  • Heffelfinger, J. D., Dowell, S. F., Jorgensen, J. H., Klugman, K. P., Mabry, L. R., Musher, D. M., Plouffe, J. F., Rakowsky, A., Schuchat, A., Whitney, C. G., and the Drug-Resistant Streptococcus pneumoniae Th, (2000). Management of Community-Acquired Pneumonia in the Era of Pneumococcal Resistance: A Report From the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 160: 1399-1408 [Abstract] [Full Text]  
  • Vergis, E. N., Indorf, A., File, T. M. Jr, Phillips, J., Bates, J., Tan, J., Sarosi, G. A., Grayston, J. T., Summersgill, J., Yu, V. L. (2000). Azithromycin vs Cefuroxime Plus Erythromycin for Empirical Treatment of Community-Acquired Pneumonia in Hospitalized Patients: A Prospective, Randomized, Multicenter Trial. Arch Intern Med 160: 1294-1300 [Abstract] [Full Text]  
  • Hammerschlag, M. R., Roblin, P. M. (2000). Microbiological Efficacy of Levofloxacin for Treatment of Community-Acquired Pneumonia Due to Chlamydia pneumoniae. Antimicrob. Agents Chemother. 44: 1409-1409 [Full Text]  
  • Zinner, S. H., Simmons, K., Gilbert, D. (2000). Comparative Activities of Ciprofloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Dynamic Model. Antimicrob. Agents Chemother. 44: 773-774 [Abstract] [Full Text]  
  • Marrie, T. J., Lau, C. Y., Wheeler, S. L., Wong, C. J., Vandervoort, M. K., Feagan, B. G., for the CAPITAL Study Investigators, (2000). A Controlled Trial of a Critical Pathway for Treatment of Community-Acquired Pneumonia. JAMA 283: 749-755 [Abstract] [Full Text]  
  • Harwell, J. I., Brown, R. B. (2000). The Drug-Resistant Pneumococcus: Clinical Relevance, Therapy, and Prevention. Chest 117: 530-541 [Abstract] [Full Text]  
  • Moss, P. J, Finch, R. G (2000). The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults. Thorax 55: 83-85 [Full Text]  
  • Entenza, J. M., Caldelari, I., Glauser, M. P., Moreillon, P. (1999). Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. J Antimicrob Chemother 44: 775-786 [Abstract] [Full Text]  
  • Geddes, A., Thaler, M., Schonwald, S., Harkonen, M., Jacobs, F., Nowotny, I. (1999). Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. J Antimicrob Chemother 44: 799-810 [Abstract] [Full Text]  
  • Haider, A. W., Luna, M., Patel, S., Gaziano, J. M., Glenn, L., Golub, L. M., Greenwald, R. A., Thompson, R. W., Hahn, D. L., Hammerschlag, M. R., Meier, C. R., Derby, L. E., Jick, S. S., Vasilakis, C., Jick, H. (1999). Antibiotic Use and Risk of Myocardial Infarction. JAMA 282: 1997-1999 [Full Text]  
  • Freidank, H. M., Losch, P., Vögele, H., Wiedmann-Al-Ahmad, M. (1999). In Vitro Susceptibilities of Chlamydia pneumoniae Isolates from German Patients and Synergistic Activity of Antibiotic Combinations. Antimicrob. Agents Chemother. 43: 1808-1810 [Abstract] [Full Text]  
  • Dedicoat, M., Venkatesan, P. (1999). The treatment of Legionnaires' disease. J Antimicrob Chemother 43: 747-752 [Full Text]  
  • Fish, D. N., Abraham, E. (1999). Pharmacokinetics of a Clarithromycin Suspension Administered via Nasogastric Tube to Seriously Ill Patients. Antimicrob. Agents Chemother. 43: 1277-1280 [Abstract] [Full Text]  
  • Lacy, M. K., Lu, W., Xu, X., Tessier, P. R., Nicolau, D. P., Quintiliani, R., Nightingale, C. H. (1999). Pharmacodynamic Comparisons of Levofloxacin, Ciprofloxacin, and Ampicillin against Streptococcus pneumoniae in an In Vitro Model of Infection. Antimicrob. Agents Chemother. 43: 672-677 [Abstract] [Full Text]  
  • (1999). New fluoroquinolone antibiotics. DTB 37: 6-8 [Abstract] [Full Text]  
  • Lister, P. D., Sanders, C. C. (1999). Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 43: 79-86 [Abstract] [Full Text]  
  • Hooper, D. C. (1998). Expanding Uses of Fluoroquinolones: Opportunities and Challenges. ANN INTERN MED 129: 908-910 [Full Text]  
  • Kaplan, S. L., Mason, E. O. Jr. (1998). Management of Infections Due to Antibiotic-Resistant Streptococcus pneumoniae. Clin. Microbiol. Rev. 11: 628-644 [Abstract] [Full Text]  
  • Edelstein, P. H. (1998). Antimicrobial Chemotherapy for Legionnaires Disease: Time for a Change. ANN INTERN MED 129: 328-330 [Full Text]  
  • Chien, S.-C., Wong, F. A., Fowler, C. L., Callery-D'Amico, S. V., Williams, R. R., Nayak, R., Chow, A. T. (1998). Double-Blind Evaluation of the Safety and Pharmacokinetics of Multiple Oral Once-Daily 750-Milligram and 1-Gram Doses of Levofloxacin in Healthy Volunteers. Antimicrob. Agents Chemother. 42: 885-888 [Abstract] [Full Text]  
  • Roblin, P. M., Hammerschlag, M. R. (1998). In Vitro Activity of a New 8-Methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 42: 951-952 [Abstract] [Full Text]  
  • Edelstein, P. H., Yu, V. L., Stout, J. E. (1998). Legionnaires' Disease. NEJM 338: 200-201 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»